This information collection
supplements FDA regulations by providing recommendations to
industry on what to include in formal meeting requests between FDA
and sponsors or applicants relating to the development and review
of drug or biological drug products regulated by FDA.
US Code:
21
USC 360bbb Name of Law: FFDCA; General Provisions Relating to
Drugs
PL: Pub.L. 115 - 52 601-611 Name of Law:
FDARA of 2017; Improvements Related to Drugs
The information collection is
being reinstated with change. We have revised the guidance document
to include relevant discussion of updated performance goals under
the FDARA of 2017. Although it currently remains a draft, we
ultimately intend to finalize the guidance. We have also made
adjustments to the annual burden hours and responses, which reflect
an increase of 83,386 and 6,153 respectively. We attribute the
adjustment to an increase in meeting requests and packages
associated with our PDUFA program.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.